DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Blau syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBlau syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for blau syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Blau syndrome is an autosomal dominant genetic disease caused by mutations in the NOD2/CARD15 gene, with fewer than 200 cases reported worldwide. In a Chinese national multicentre study of 72 patients, the mean age of onset was 14.30 months and all patients developed symptoms before 5 years old. 87.50% had granulomatous arthritis, 65.28% had rash, 36.11% had ocular involvement, 27.78% had fever, and 15.28% had pulmonary involvement. The main mutations were p.R334Q and p.R334W; patients with p.R334Q had a relatively higher incidence of fever (35.71% vs 14.29%) and ocular involvement (42.86% vs 28.57%), while those with p.R334W had a relatively higher incidence of rash (85.71% vs 64.29%), though none of these differences reached statistical significance.
Long-term visual outcomes are poor. In a retrospective cohort of 13 genetically confirmed patients, anterior uveitis was the most common presentation at baseline (57.1%), but all patients with uveitis lasting 10 years or more developed panuveitis. Median logMAR visual acuity was 0 at baseline, 0.19 at year 5, and 0.7 at year 20, with one eye progressing to no perception of light. Disease control, defined as cells <1+ in both eyes and topical steroid use less than twice daily, was achieved in only 14.3% to 37.5% of patients at various time points despite treatment with topical and oral steroids and multiple systemic immunosuppressants including biologics. Cataract surgery was needed in 12 eyes of 8 patients, glaucoma surgery in 3 eyes, and retinal detachment surgery in 4 eyes.
Treatment in the Chinese cohort consisted of glucocorticoid combined with methotrexate in 62.50% of patients, with 22 patients also receiving a tumour necrosis factor antagonist. In a separate centre, 6 cases were using anti-TNF agents (adalimumab in 4, infliximab in 2). A general review notes that treatment focuses on symptom control with non-steroidal anti-inflammatory drugs, corticosteroids, and in severe cases immunosuppressive agents, and that multidisciplinary collaboration is essential.
What is still missing are prospective trials that test specific biologic agents against standard immunosuppression in defined patient subgroups, a reliable biomarker to predict which patients will progress to severe eye or joint disease, and funding for a registry large enough to stratify outcomes by genotype and age at treatment initiation. The existing evidence is retrospective, drawn from small cohorts, and cannot distinguish whether early biologic use prevents visual loss or merely reflects more aggressive disease.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
International Journal of Rheumatic Diseases · 2023 · 1 citations
Blau syndrome with <scp>NOD2</scp> mutation in a <scp>54‐year‐old</scp> man: A case report
AbstractBlau syndrome (BS) is a rare genetic immune disease which commonly presents in childhood. Currently, the miss-rate of BS diagnosis is very high, and an effective clinical management of BS has not been well established. This case report depicts a 54-year-old male Chinese patient presenting with hand malformation, fever, skin rash and joint pain. His diagnosis was ultimately confirmed according to typical medical history and genetic analysis. This case report will further help clinicians to be aware of this rare clinical entity for correct diagnosis and proper treatment.
Long-Term Visual Outcome of Patients with Blau Syndrome
AbstractTo document the long-term visual outcomes in patients with Blau syndrome. A retrospective institutional cohort study was conducted, and 13 patients with genetically confirmed Blau syndrome were included. Demographic and clinical data were collected from standardised medical charts. Baseline was defined as the first detected uveitis and data were recorded onwards at intervals of 1, 3, 5, 10, 15 and 20 years. Anterior uveitis was the most common classification at baseline (57.1%). Among patients with documented uveitis lasting 10 years or more, all of them developed panuveitis. Median logMAR visual acuity at baseline was 0 (range −0.5; 0.7), 0.19 (range 0; 1.5) at year 5, and 0.7 (range 0.1 – no perception of light) at year 20, as recorded in 13, 16, and 10 eyes, respectively. All patients received treatment with topical and oral steroids, and multiple systemic immunosuppressants including biologics. Disease control, defined as having cells <1+ in both eyes and using topical steroid eye drops less than twice daily, was achieved in 14.3% to 37.5% of patients at the different time points. Cataract surgery was performed in 12 eyes of 8 patients, 3 eyes of 3 patients necessitated glaucoma surgery, and 4 eyes of 4 patients required surgery for retinal detachment. Uveitis associated with Blau syndrome commonly leads to severe, chronic panuveitis, requiring long-term systemic immunosuppression. Early diagnosis and timely initiation of biologics may prevent significant visual impairment.
DOAJ (DOAJ: Directory of Open Access Journals) · 2022 · 0 citations
Clinical Characteristics and Treatment of Blau Syndrome in Chinese Children-a National Multicenter Study
AbstractObjective To study the demographic and clinical characteristics, correlation of genotype and phenotype and treatment of Blau syndrome to facilitate early diagnosis and timely treatment of Blau syndrome. Methods Seventy-two patients with Blau syndrome from 11 centers from May 2006 to April 2022 were retrospectively analyzed, and their general information, clinical data, laboratory examination and treatment medication were collected. Results The distribution of patients with Blau syndrome was uniform in geographical north and south of China, and there was no obvious gender bias. The mean age of onset was (14.30±12.81) months, and the age of diagnosis was (55.18±36.22) months. 35% of patients with Blau syndrome happened before 1 year old, and all patients developed before 5 years old. 87.50% (63/72) had granulomatous arthritis, 65.28% (47/72) had rash, 36.11% (26/72) had ocular involvement, 27.78% (20/72) had fever, and 15.28% (11/72) had pulmonary involvement. Arthritic manifestations of Blau syndrome were most at risk, followed by rash, ocular involvement, and fever.The first 25 months of the disease, the risk of developing a rash was the greatest. The risk of developing arthritis was the greatest between 25 months and 84 months. The main mutations were p.R334Q and p.R334W, and patients with p.R334Q mutation had relatively high incidence of fever (35.71%[5/14] vs. 14.29%[1/7], P=0.43) and ocular involvement (42.86%[6/14]vs. 28.57%[2/7], P=0.51). There was a relatively high incidence of rash (85.71%[6/7] vs. 64.29%[9/14], P=0.59) in patients with the p.R334W mutation. Forty-five patients(62.50%)were treated with a combina-tion of glucocorticoid and methotrexate. Twenty-two patients were treated with tumor necrosis factor antagonist in addition to glucocorticoid and methotrexate. Conclusions The risk of different clinical manifestations of Blau syndrome from high to low was arthritis, followed by rash, ocular involvement and fever. The main treatment was glucocorticoid combined with methotrexate, to which biological agents could be added.
Additional file 2 of A Chinese girl of Blau syndrome with renal arteritis and a literature review
AbstractAdditional file 2: Fig. S1. Current treatment of patients with Blau syndrome in our center. (A) Systemic therapy. We calculated all drugs of every patient in this graph. (B) Biologics. 6 cases were using anti-tumor necrosis factor (TNF) agents, including adalimumab in 4 cases and infliximab in 2cases. (C) Combination therapy of other therapies and biological agents. NSAIDs, non-steroidal anti-inflammatory drugs; MTX, methotrexate; PSL, prednisolone; Bio, biologics.
Additional file 2 of A Chinese girl of Blau syndrome with renal arteritis and a literature review
AbstractAdditional file 2: Fig. S1. Current treatment of patients with Blau syndrome in our center. (A) Systemic therapy. We calculated all drugs of every patient in this graph. (B) Biologics. 6 cases were using anti-tumor necrosis factor (TNF) agents, including adalimumab in 4 cases and infliximab in 2cases. (C) Combination therapy of other therapies and biological agents. NSAIDs, non-steroidal anti-inflammatory drugs; MTX, methotrexate; PSL, prednisolone; Bio, biologics.
Greater South Information System · 2023 · 0 citations · open access
Blau Syndrome: A Rare Multisystemic Genetic Disease with Distinctive Clinical Manifestations
AbstractBlau syndrome is an extremely rare genetic disease characterized by a multisystemic clinical presentation affecting the skin, joints, eyes and nervous system. It is an autosomal dominantly inherited disease caused by mutations in the NOD2/CARD15 gene. This disease predominantly affects children, although adult-onset cases have been reported. The epidemiology of Blau syndrome is limited due to its low prevalence, with fewer than 200 cases reported worldwide. Diagnosis is based on clinical evaluation and molecular genetic testing to identify mutations in the NOD2/CARD15 gene. Treatment focuses on symptom control and reduction of inflammation, using non-steroidal anti-inflammatory drugs, corticosteroids and, in more severe cases, immunosuppressive agents. Multidisciplinary collaboration between different medical specialties is essential for the comprehensive management of patients. Although advances have been made in the understanding of Blau syndrome, more research is still needed to elucidate its pathophysiology, epidemiology and therapeutic options.
Greater South Information System · 2023 · 0 citations · open access
Blau Syndrome: A Rare Multisystemic Genetic Disease with Distinctive Clinical Manifestations
AbstractBlau syndrome is an extremely rare genetic disease characterized by a multisystemic clinical presentation affecting the skin, joints, eyes and nervous system. It is an autosomal dominantly inherited disease caused by mutations in the NOD2/CARD15 gene. This disease predominantly affects children, although adult-onset cases have been reported. The epidemiology of Blau syndrome is limited due to its low prevalence, with fewer than 200 cases reported worldwide. Diagnosis is based on clinical evaluation and molecular genetic testing to identify mutations in the NOD2/CARD15 gene. Treatment focuses on symptom control and reduction of inflammation, using non-steroidal anti-inflammatory drugs, corticosteroids and, in more severe cases, immunosuppressive agents. Multidisciplinary collaboration between different medical specialties is essential for the comprehensive management of patients. Although advances have been made in the understanding of Blau syndrome, more research is still needed to elucidate its pathophysiology, epidemiology and therapeutic options.
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access
Blau Syndrome: A Rare Multisystemic Genetic Disease with Distinctive Clinical Manifestations
AbstractBlau syndrome is an extremely rare genetic disease characterized by a multisystemic clinical presentation affecting the skin, joints, eyes and nervous system. It is an autosomal dominantly inherited disease caused by mutations in the NOD2/CARD15 gene. This disease predominantly affects children, although adult-onset cases have been reported. The epidemiology of Blau syndrome is limited due to its low prevalence, with fewer than 200 cases reported worldwide. Diagnosis is based on clinical evaluation and molecular genetic testing to identify mutations in the NOD2/CARD15 gene. Treatment focuses on symptom control and reduction of inflammation, using non-steroidal anti-inflammatory drugs, corticosteroids and, in more severe cases, immunosuppressive agents. Multidisciplinary collaboration between different medical specialties is essential for the comprehensive management of patients. Although advances have been made in the understanding of Blau syndrome, more research is still needed to elucidate its pathophysiology, epidemiology and therapeutic options.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
